By: Coherent Market Insights
U.S. Medical Foods Market Report Analyses competitive environment such as key players, future trends, growths, challenges and acquisitions in the market.
Foods Market, by Food Type (Prebiotics, Probiotics, and Food Supplements), by Disease Indication (Inflammatory Bowel Disease, Irritable Bowel Syndrome, and Others), and by Distribution Channel (Hospitals, Retail Channel, and Online Channel), was valued at US$ 10,991.5 million in 2019, and is expected to exhibit a CAGR of 17.1% over the forecast period (2019-2027), as highlighted in a new report published by . Key players in the market are focused on strengthening their market position by collaborating with other manufacturers for development and commercialization of efficient medical food products.
Browse 36 Market Data Tables and 30 Figures spread through 102 Pages and in-depth TOC on “U.S. Medical Foods Market”- Forecast to 2027, by Food Type (Prebiotics, Probiotics, and Food Supplements), by Disease Indication (Inflammatory Bowel Disease, Irritable Bowel Syndrome, and Others), and by Distribution Channel (Hospitals, Retail Channel, and Online Channel)
For instance in January 2016, Enterome SA entered into a collaborative research agreement with Janssen Biotech, Inc. for discovery of novel targets and therapeutic agents for Crohn’s disease.
Browse Research Report: https://www.coherentmarketinsights.com/market-insight/us-medical-foods-market-3215
Key Takeaways of the U.S. Medical Foods Market:
The U.S. medical foods market is expected to exhibit a CAGR of 17.1% over the forecast period, owing to increasing awareness about medical foods in the U.S. and rising risks of gastrointestinal disease such as Cohn’s diseases or ulcerative colitis in the U.S.
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/3215
Among food type, probiotic segment held a largest market share in 2018 owing to rising demand for medical foods and increasing presence of market players in U.S., is expected to propel growth of the probiotic market in the U.S. medical foods market over the forecast period.
Among disease indication, irritable bowel syndrome (IBS) segment held a higher market share in 2018 owing to increasing patient pool suffering from IBS in the U.S. For instance, according to the International Foundation for Gastrointestinal Disorders (IFFGD) 2016, in the U.S., around 2.4 million and 3.5 million people visited hospitals and clinics, for the treatment of IBS.
Companies operating in the U.S. medical foods market include Enterome SA, Yakult Honsha Co., Ltd., Abbott, ExeGi Pharma, LLC, VSL Pharmaceuticals, Inc., Entera Health, Inc., Meiji Holdings Co., Ltd., Danone, and Nestlé S.A.